aod 9604 and tirzepatide AOD-9604 - 10mg AOD-9604, Compounded 5 mg/vial |

Description

People with obesity and no diabetes who took 36 mg for 72 weeks lost 12.4 percent of their body weight, according to another 2025 study, coauthored by Dr

Combination Therapy in Hypertensive Diabetic Patients A study on the combination of empagliflozin and metformin in patients with hypertension and type 2 diabetes mellitus (T2DM) found that adding empagliflozin to a regimen that includes metformin and lisinopril significantly improved glycemic control, blood pressure regulation, and promoted weight loss

The trials used different designs and populations

Monzio Compagnoni, G

The company also defended the safety of its active pharmaceutical ingredients, stating: "The APIs used to compound our Semaglutide and Tirzepitide (S&T) are sourced from reputable, internationally approved pharmaceutical manufacturers and have been tested in independent analytical laboratories for sterility and quality." In a striking claim, iDexis insisted it had dispensed its compounded product to over 200,000 patients without incident, writing: "To date we have dispensed our S&T compounded peptide product to 214 406 patients on prescription of their treating clinicians through the practices of their clinicians, or retail pharmacies of choice, without any reports of adverse reactions or conditions, only reports of great success and gratitude being expressed." iDexis went further, accusing SAHPRA of attempting to improperly influence the outcome of an ongoing court case: "We are of the opinion that the impugned findings of SAHPRA are nothing other than unsophisticated attempts orchestrated to improperly influence the outcome of the court case, especially in the light of the official investigation by SAHPRA launched in 2025 into the desirability of compounding peptides, in respect of which SAHPRA has not published any findings to date." The matter is scheduled to be heard in the Gauteng High Court in Pretoria on June 10 and 11, 2026